DAFTAR PUSTAKA
Abbate, A., Biondi-Zoccal, G.G.L., Agostoni, P., Lipinski, M., Vetrovec, G. 2007.
Recurrent angina after coronary revascularization: a clinical challenge.
European Heart Journal. 28: 1057-1065.
Abrams, J. 2005. Chronic Stable Angina. N Engl J Med. 352: 2524-33.
Anderson, J.L., Adams, C.D., Antman, E.M., Bridges, C.R., Califf, R.M., Casey,
D.E., et al. 2011. Guidelines for the management of patients with unstable
angina/non-ST-elevation myocardial infarction: A report of the American
College of Cardiology Foundation/American Heart Association task force
on practice guidelines. Circulation. 123: e426-e579.
Barua, R.S., Sy, F., Srikanth, S., Huang, G., Javed, U., Buhari, C., et al. 2010.
Acute cigarette smoke exposure reduces clot lysis – association between
altered fibrin architecture and the response to t-PA. Thrombosis Research.
126: 426-30.
Barua, R.S., Sy, F., Srikanth, S., Huang, G., Javed, U., Buhari, C., et al.2010.
Effects of cigarette smoke exposure on clot dynamics and fibrin structure:
An ex vivo investigation. Arterioscler Thromb Vasc Biol. 30: 75-9.
Bassuk, S.S., Ridker, P.M. 2006. C-reactive protein as a tool for risk assessment
in primary prevention. In: Morrow, D.A. editor. Cardiovascular Biomarkers:
Pathophysiology and Disease Management. New Jersey. Humana
Press.p.237-260.
Buffon, A., Liuzzo, G., Biasucci, L.M., Pasqualetti, P., Ramazzotti, V., Rebuzzi,
A.G., et al. 1999. Preprocedural serum level of c-reactive protein predict
early complications and late restenosis after coronary angioplasty. J Am
Cannon, C.P., Brindis, R.G., Chaitman, B.R., Cohen, D.J., Cross, J.T., Drozda,
J.P., et al. 2013. ACCF/AHA Key data elements and definition for
measuring the clinical management and outcomes of patients with acute
coronary syncromes and coronary artery disease: a report of the American
College of Cardiology Foundation/American Heart Association task force
on clinical data standards. Circulation. 127: 1052-1089.
Choi, H., Cho, D.H., Shin, H.H., Park, J.B. 2004. Association of high sensitivity
C-reactive protein with coronary heart disease prediction, but not with
carotid atherosclerosis, in patients with hypertension. Circulation. 68:
297-303.
DeWinter, R.J., Heyde, G.S., Koch, K.T., Fischer, J., VanStraalen, J.P., Bax, M.,
et al. 2002. The prognostic value of pre-procedural plasma c-reactive protein in patients undergoing elective coronary angioplasty. Eur Heart J.
23: 960-6.
Dibra, A., Mehilli, J., Braun, S., Hadamitzky, M., Baum, H., Dirschinger, J., et al.
2003. Association between c-reactive protein levels and subsequent cardiac
events among patients with stable angina treated with coronary artery
stenting. Am J Med. 114: 715-22.
Dwyer, G.B. 2014. Physical activity preparticipation screening guidelines. In:
Lupash, E. editor. ACMS’s Resources for the Health Fitness Specialist. 1st
ed. Philadelphia.Wolters Kluwer Health: Lippincott
Williams&Wilkins.p.25.
Gach, O., Legrand, V., Biessaux, Y., Chapelle, J.P., Vanbelle, S., Pierard, L.A.
2007. Long-term prognostic significance of high-sensitivity C-reactive
protein before and after coronary angioplasty in patients with stable angina
Ganter, M.T., Hofer, C.K. 2008. Coagulation monitoring, current techniques and
clinical use of viscoelastic point-of-care coagulation device. Anesth Analg.
106: 1366-1375.
Garg, R., Tellez, A., Alviar, C., Granada, J., Kleiman, N.S., Lev, E.I. 2008. The
effect of percutaneous coronary intervention on inflammatory response and
endotelial progenitor cell recruitment. Catheterization and cardiovascular
interventions. 72: 205-9.
Gregory, Y.H., Blann, A.D. 2000. Does hypertension confer a prothrombotic
state? Virchow’s triad revisited. Circulation. 101: 218-20.
Gurbel, P.A., Bliden, K.P., Guyer, K., Cho, P.W., Zaman, K.A., Kreutz, R.P., et
al. 2005. Platelet reactivity in patients and recurrent events post-stenting. J Am Coll Cardiol. 46: 1820-1826.
Hansson, G.K. 2005. Inflammation, atherosclerosis, and coronary artery disease.
N. Engl. J. Med. 352: 1685-1695.
Haverkate, F., Thompson, S.G., Pyke, S.D., Gallimore, J.R., Pepys, M.B. 1997.
Production of c-reactive protein and risk of coronary events in stable and
unstable angina: European concerted action on thrombosis and disabilities
angina pectoris study group. Lancet. 349: 462-466.
Holmes, D.R., Kereiakes D.J., Garg, S., Serruys P.W., Dehmer, G.J., Ellis, S.G.,
et al. 2010. Stent thrombosis. J Am Coll Cardiol. 56: 1357-65.
Hoshida, S., Nishino, M., Takeda, T., Tanouchi, J., Yamada, Y., Hori, M. 2004. A
persistent increase in c-reactive protein in a risk factor for restenosis in
patients with stable angina who are not receiving statins. Atherosclerosis.
Inoue, T., Kato, T., Uchida, T., Sakuma, M., Nakajima, A., Shibazaki, M., et al.
2005. Local release of c-reactive protein from vulnerable plaque or coronary
arterial wall injured by stenting. J Am Coll Cardiol. 46: 239-245.
Kaptoge, S., Di Angelantonia, E., Lowe, G., Pepys, M.B., Thompson, S.G.,
Collins, R., et al. 2010. C-reactive protein concentration and risk of
coronary heart disease, stroke, and mortality: an individual meta-analysis.
Lancet. 375: 132-140.
Khera, A., McGuire, D.K., Murphy, S.A., Stanek, H.G., Das, S.R.,
Vongpatanasin, W., et al. 2005. Race and gender differences in c-reactive
protein levels. J Am Coll Cardiol. 46: 464-9.
Kralisz, P., Kemona, H., Dobrzycki, S., Bachorzewska-Gajewska, H., Nowak, K.,
Sawicki, Z. 2006. Changes in c-reactive protein levels following coronary
stent implantation depend on the extent of peroprocedural arterial injury.
Kardiol Pol. 64: 364-371.
Kreutz, R.P., Owens, J., Breall, J.A., Lu, D., Lohe E., Bolad, I., et al. 2013.
C-reactive protein and fibrin clot strength measured by thromboelastography
after coronary stenting. Blood Coagul Fibrinolysis. 24: 321-326.
Libby, P. 2006. Inflammation in cardiovascular disease. In: Morrow, D.A. editor.
Cardiovascular Biomarkers: Pathophysiology and Disease Management.
New Jersey. Humana Press.p.207-221.
Libby, P., Ridker, P.M., Hansson, G.K. 2009. Inflammation in atherosclerosis. J
Am Coll Cardiol. 54: 2129-38.
Liuzzo, G., Biasucci, L.M., Gallimore, J.R., Grillo, R.L., Rebizzu, A.G., Pepys,
amyloid a protein in severe unstable angina pectoris. N. Engl J Med. 331:
417-424.
Mansfield, M.W., Heywood, P.M., Grant, P.J. 1996. Sex differences in
coagulation and fibrinolysis in white subjects with non-insulin dependent
diabetes mellitus. Atherosclerosis, Thrombosis, and Vascular Biology. 16:
160-4.
McCrath, D., Cerboni, E., Hirsh, A., Frumento R.J., Bennet-Guerrero, E. 2003.
Association of thromboelastography (MA) and thrombotic complications
after major non-cardiac surgery. Anesth Analog. 96:SCA1-141.
Nakagomi, A., Freedmann, S.B., Geczy, C.L. 2000. Interferon-gamma and
lipopolysaccharide potentiate monocyte tissue factor induction by c-reactive
protein relationship with age, sex, and hormone replacement treatment.
Circulation. 101: 1785-91.
Nyandak, T., Gogna, A., Bansal, S., Deb, M. 2007. High sensitive c-reactive
protein (hs-CRP) and its correlation with angiographic severity of coronary
artery disease. JIACM. 8: 217-221.
Park, D., Yun, S., Lee, J., Kim, W., Kang, S., Lee, S., et al. 2009. C-reactive
protein and the risk of stent thrombosis and cardiovascular events after
drug-eluting stent implantation. Circulation. 120: 1987-1995.
Ridker, P.M., Cannon, C.P., Morrow, D., et al. 2005. C-reactive protein levels and
outcomes after statin therapy. N Eng J Med. 352: 20-8.
Rifai, N. 2006. Analytic issues for clinical use of c-reactive protein. In: Morrow,
D.A. editor. Cardiovascular Biomarkers: Pathophysiology and Disease
Rifai, N., Ridker, P.M. 2001. High-sensitivity c-reactive protein: A novel and
promising marker of coronary heart disease. Clinical Chemistry. 47:
403-411.
Song, C.J., Nakagomi, A., Chandar, S., Cai, H., Lim, I.G.S., McNeil, H.P., et al.
2006. C-reactive protein contributes to the hypercoagulable state in coronary
artery disease. J Thromb Haemost. 4: 98-106.
Steinhubl, S., Berger, P., Mann, J.T., Fry, E.T.A., DeLago, A., Wilmer, C. et.al.
2007. Early and sustained dual oral antiplatelet therapy following
percutaneous coronary intervention. JAMA. 288: 2411-2420.
Thakur, M., Ahmed, A.B. 2012. A review of thromboelastography. International
Journal of Perioperative Ultrasound and Applied Technologies. 1: 25-29.
Thygesen, K., Alpert J.S., Jaffe, A.S., Simoons, M.L., Chaitman, B.R., White,
H.D. 2012. Third universal definition of myocardial infarction. European
Heart Journal. doi:10.1093/eurheartj/ehs184
Toutouzas, K., Colombo, A., Stefanadis, C. 2004. Inflammation and restenosis
after percutaneous coronary interventions. European Heart Journal. 25:
1679-1687.
Undas, A., Areins, R.A.S. 2011. Fibrin clot structure and fuction: A role in the
pathophysiology thromboembolic disease. Arterioscler Thromb Vasc Biol.
31: e88-e99.
Undas, A., Plicner, D., Stepien, E., Drwila, R., Sadowski, J. 2007. Altered fibrin
clot structure in patients with advances coronary artery disease: a role of
C-reactive protein, lipoprotein(a), and homocysteine. J Thromb Haemost. 5:
Undas, A., Zalewski, J., Krochin, M., Siudak, Z., Sadowski, M., Pregowski, J., et
al. 2010. Altered plasma fibrin clot properties are associated with in-stent
thrombosis. Arteriscler Thromb Vasc Biol. 30: 276-282.
Weintraub, W.S., Karlsberg, R.P., Tcheng, J.E., Boris, J.R., Buxton, A.E., Dove,
J.T., et al. 2011. Key data elements and definition of a bas cardiovascular
vocabulary for electronic health records. J Am Coll Cardiol. 58: 202-222.
Zalewski, J., Undas, A., Godlewski, J., Stepien, E., Zmudka, K. 2007. No-reflow
phenomenon after acute myocardial infarction is associated with reduced
clot permeability and susceptibility to lysis. Arteriscler Thromb Vasc Biol.
